BunyaVax

Overview
Animal Therapeutics?
Product stageSegments
Early
?
Next-generation vaccines and drugs
?

BunyaVax exploits proprietary vaccine platform technology to develop safe and efficacious vaccines against infectious diseases and cancer. The unique ‘Plug and Play’ platforms are used to generate potent vaccines that can encode almost any antigen of interest. Applications are in the veterinary and human setting.

HQ location:
Houtribweg 39 Lelystad NLD
Founded year:
2017
Employees:
1-10
IPO status:
Private
Total funding:
USD 83.3 k
Last Funding:
USD 83.3 k (Grant; Jun 2018)
Last valuation:
-
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.